Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.68 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.57 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.57 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.57 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.40 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.40 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29744352 | 1.00 | MAPT (0.68) | MAPTCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL29744389 | 1.00 | MAPT (0.68) | MAPTCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL23497899 | 1.00 | MAPT (0.68) | MAPTCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL23498290 | 1.00 | MAPT (0.68) | MAPTCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL25374924 | 0.92 | CHRNB2 (0.63) | MAPTCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL25372739 | 0.92 | CHRNB2 (0.63) | MAPTCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL16888506 | 0.84 | MAPT (0.73) | MAPTCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL17054802 | 0.84 | MAPT (0.68) | MAPTCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL3539759 | 0.82 | MAPT (0.90) | MAPTCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL29435521 | 0.82 | MAPT (0.97) | MAPTCHRNB2CHRNA4CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170247373-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247373-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | MAPT 1236/4885CHRNB2 3189/4885CHRNA4 4028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.